Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
71.18-0.79 (-1.10%)
As of 10:37AM EDT. Market open.
| Previous close | 71.97 |
| Open | 71.19 |
| Bid | 71.04 x 1400 |
| Ask | 71.07 x 800 |
| Day's range | 70.89 - 71.36 |
| 52-week range | 68.44 - 82.35 |
| Volume | 5,624,685 |
| Avg. volume | 9,979,089 |
| Market cap | 180.232B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 25.71 |
| EPS (TTM) | 2.77 |
| Earnings date | 28 Oct 2021 |
| Forward dividend & yield | 2.60 (3.45%) |
| Ex-dividend date | 14 Sept 2021 |
| 1y target est | 93.21 |
- Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
KENILWORTH, N.J., September 17, 2021--Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination with Chemo for Certain Patients with Metastatic TNBC
- Zacks
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
- Yahoo Finance Video
Biden meets with CEOs, business leaders on vaccine mandates
Yahoo Finance’s Jessica Smith reports what to expect from Biden’s meeting on vaccine mandates with top business executives.
© 2021 Verizon Media. All rights reserved.
